| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
| Targets |
Phenazopyridine does not have a specific receptor target. It is a local anesthetic that acts on the mucosa of the urinary tract to provide symptomatic relief from pain, burning, and discomfort. Its mechanism involves a topical analgesic effect on the bladder and urethral lining.
|
|---|---|
| ln Vitro |
In vitro, Phenazopyridine is used to study its effects on neuronal cells. It has been reported to induce neuronal differentiation of embryonic stem cells (ESCs). It is also used in research on traumatic brain injury and neurodegenerative diseases.
|
| ln Vivo |
In vivo, Phenazopyridine is administered orally to patients for the symptomatic relief of urinary tract pain. It is not a cure for the underlying infection but provides relief from discomfort. It is also used in animal models to study its effects on pain and neurological conditions.
|
| Enzyme Assay |
In vitro, neuronal cell lines or primary neurons are treated with Phenazopyridine. The compound is typically dissolved in DMSO. Effects on cell differentiation, survival, and signaling pathways are assessed. It is used to study its neuroprotective or neurotoxic properties.
|
| Cell Assay |
In cell-based assays, various cell types, including embryonic stem cells, are treated with Phenazopyridine. The compound is dissolved in a suitable solvent and added to the culture medium. After incubation, cellular differentiation, proliferation, and viability are assessed.
|
| Animal Protocol |
In vivo, Phenazopyridine is administered orally to animal models. The dosage and route of administration depend on the specific research model. Efficacy is evaluated by measuring pain relief or changes in neurological function.
|
| ADME/Pharmacokinetics |
Phenazopyridine has a molecular weight of 189.22 and formula C11H11N5. It is a brick-red microcrystalline powder with a slight violet luster. It has a slightly bitter taste. It is slightly soluble in cold water (1:300) and soluble in boiling water (1:20). Storage: Amber vial, -20°C, under inert atmosphere.
|
| Toxicity/Toxicokinetics |
Effects During Pregnancy and Lactation
◉ Overview of Use During Lactation The safety of phenapyridine in infants or breastfeeding women has not been established. Because it can cause methemoglobinemia, sulfohmoglobinemia, and hemolytic anemia, it should be avoided in breastfeeding women, especially infants under 1 month of age or infants with glucose-6-phosphate dehydrogenase (G6PD) deficiency. ◉ Effects on Breastfed Infants No published information found as of the revision date. ◉ Effects on Lactation and Breast Milk No published information found as of the revision date. Phenazopyridine may cause a reddish-orange discoloration of urine and other bodily fluids. It may cause hemolytic anemia in patients with G6PD deficiency. It is for research use only and not for human therapeutic use outside approved indications. |
| References | |
| Additional Infomation |
According to an independent committee of scientific and health experts, phenapyridine may be carcinogenic. Phenapyridine is a diaminopyridine, a 2,6-diaminopyridine with a phenyl azo group substituted at the 3-position. It is a local anesthetic with local analgesic effects on the mucous membranes of the urinary tract. Its use is limited due to its toxicity (primarily blood disorders) and potential carcinogenicity concerns. It is used as a local anesthetic, a non-narcotic analgesic, a carcinogen, and an anti-coronavirus drug. It is a diaminopyridine and monoazo compound, the conjugate base of phenapyridine (1+). It is a local anesthetic used to treat urinary tract disorders. Its use is limited due to its toxicity (primarily blood disorders) and potential carcinogenicity concerns. See also: Phenapyridine (note moved to).
Phenazopyridine is also known as Pyridium. It is a urinary tract analgesic used for the short-term management of urinary tract irritation. |
| Molecular Formula |
C11H11N5
|
|---|---|
| Molecular Weight |
213.24
|
| Exact Mass |
213.101
|
| CAS # |
94-78-0
|
| Related CAS # |
Phenazopyridine hydrochloride;136-40-3
|
| PubChem CID |
4756
|
| Appearance |
Orange to red solid powder
|
| Density |
1.32g/cm3
|
| Boiling Point |
442.3ºC at 760mmHg
|
| Melting Point |
235 - 240ºC
|
| Index of Refraction |
1.6880 (estimate)
|
| LogP |
3.823
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
16
|
| Complexity |
237
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
NC1=CC=C(/N=N/C2=CC=CC=C2)C(N)=N1
|
| InChi Key |
QPFYXYFORQJZEC-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C11H11N5/c12-10-7-6-9(11(13)14-10)16-15-8-4-2-1-3-5-8/h1-7H,(H4,12,13,14)
|
| Chemical Name |
3-phenyldiazenylpyridine-2,6-diamine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.6896 mL | 23.4478 mL | 46.8955 mL | |
| 5 mM | 0.9379 mL | 4.6896 mL | 9.3791 mL | |
| 10 mM | 0.4690 mL | 2.3448 mL | 4.6896 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
